By Nick Robertson ( August 11, 2025, 17:12 GMT | Insight) -- BioNTech and Pfizer have reached a $500 million settlement with GlaxoSmithKline in patent infringement litigation related to mRNA vaccines for COVID-19 and the flu, including a non-exclusive patent license, following the sale of CureVac to BioNTech.BioNTech, Pfizer, GlaxoSmithKline and CureVac announced Thursday that they have reached a framework to settle all pending patent litigation between the companies related to mRNA vaccine patents owned by CureVac. The deal, worth up to $500 million, follows the $1.25 billion purchase by BioNTech of fellow German vaccine manufacturer CureVac first touted in June....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.